Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 6th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Revenue	EBITDA	Earnings	EPS	Rev. Y/Y	Rev. 5Y	Earn. Y/Y	Earn. 5Y	Earnings Date
NVS	NOVARTIS AG	$231.37B	$53.22B	$26.42B	$12.86B	$6.44	11.50%	1.29%	-12.62%	3.93%	2025-07-17
JNJ	JOHNSON & JOHNSON	$373.47B	$89.33B	$34.70B	$21.81B	$9.06	4.30%	1.55%	-40.63%	6.83%	2025-07-16
GRFS	GRIFOLS SA	$6.25B	$8.01B	$1.71B	$174.36M	$0.26	2.57%	5.57%	258.21%	-25.16%
ABBV	ABBVIE INC	$337.14B	$57.37B	$14.30B	$4.20B	$2.36	5.45%	10.99%	-29.97%	-16.08%	2025-07-23
AZN	ASTRAZENECA PLC	$228.01B	$68.50B	$17.68B	$7.77B	$2.51	13.70%	22.09%	22.49%	34.22%
GSK	GSK PLC	$82.76B	$41.49B	$6.16B	$4.15B	$2.03	3.90%	-0.93%	-29.12%	-9.52%	2025-07-29
AMGN	AMGEN INC	$158.92B	$34.13B	$15.28B	$5.93B	$11.05	15.56%	7.32%	56.96%	-2.97%	2025-08-04
BMY	BRISTOL MYERS SQUIBB CO	$99.03B	$47.64B	$14.17B	$5.42B	$2.68	4.62%	8.97%	N/A	33.17%	2025-07-31
LLY	ELI LILLY & CO	$765.37B	$49.00B	$15.43B	$11.11B	$12.34	36.38%	16.24%	80.94%	15.25%
GILD	GILEAD SCIENCES INC	$137.86B	$28.74B	$10.58B	$5.97B	$4.77	4.68%	4.81%	1,092.50%	4.06%
MRK	MERCK & CO INC	$203.29B	$63.92B	$26.05B	$17.43B	$6.89	4.10%	9.63%	657.14%	11.60%	2025-07-29
PFE	PFIZER INC	$138.72B	$62.46B	$14.27B	$7.88B	$1.39	11.65%	10.53%	N/A	-13.01%	2025-07-28
BIIB	BIOGEN INC	$19.20B	$9.82B	$2.52B	$1.48B	$10.16	1.59%	-7.41%	26.21%	-20.72%	2025-07-30
SCLX	SCILEX HOLDING CO	$33.30M	$50.71M	-$65.87M	-$74.51M	-$14.16	7.79%	N/A	N/A	N/A
SNY	SANOFI	$124.82B	$46.13B	$11.90B	$5.79B	$2.31	-0.24%	1.76%	-3.38%	13.35%	2025-07-23
OGN	ORGANON & CO	$2.65B	$6.29B	$1.48B	$750.00M	$2.91	-0.84%	N/A	-29.02%	N/A
AMRN	AMARIN CORP PLC	$287.41M	$214.11M	-$78.68M	-$87.93M	-$4.40	-22.83%	-15.98%	N/A	N/A
MIRA	MIRA PHARMACEUTICALS INC	$21.15M	$0.00	-$8.03M	-$7.92M	-$0.51	N/A	N/A	N/A	N/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jun 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Novartis Ag (NYSE:NVS)

Novartis Ag (NYSE:NVS) is the #1 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: B.

Novartis Ag (NYSE:NVS) has a Due Diligence Score of 37, which is -6 points lower than the general drug manufacturer industry average of 43. Although this number is below the industry average, our proven quant model rates NVS as a "A".

NVS passed 13 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 12.54% over the past year, overperforming other general drug manufacturer stocks by 22 percentage points.

2. Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) is the #2 top general drug manufacturer stock out of 18 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Johnson & Johnson (NYSE:JNJ) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: B, and AI: A.

Johnson & Johnson (NYSE:JNJ) has a Due Diligence Score of 51, which is 8 points higher than the general drug manufacturer industry average of 43.

JNJ passed 18 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock return 6.35% over the past year, overperforming other general drug manufacturer stocks by 15 percentage points.

Johnson & Johnson has an average 1 year price target of $163.60, an upside of 5.4% from Johnson & Johnson's current stock price of $155.22.

Johnson & Johnson stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Johnson & Johnson, 10% have issued a Strong Buy rating, 20% have issued a Buy, 70% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #3 top general drug manufacturer stock out of 18 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: B, Growth: B, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: B.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 30, which is -13 points lower than the general drug manufacturer industry average of 43. Although this number is below the industry average, our proven quant model rates GRFS as a "B".

GRFS passed 12 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 28.03% over the past year, overperforming other general drug manufacturer stocks by 37 percentage points.

What are the general drug manufacturer stocks with highest dividends?

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 5.69%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.35%.

Organon & Co's dividend payout ratio of 38.5% indicates that its high dividend yield is sustainable for the long-term.

2. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 5.2%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.35%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 121.6% indicates that its high dividend yield might not be sustainable for the long-term.

3. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.48%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.35%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 88.1% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -0.74% in the last day, and up 1.8% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are down.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 13 points higher than the general drug manufacturer industry average of 44. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -36.5% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -27 percentage points.

2. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 27 points higher than the general drug manufacturer industry average of 44. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -49.93% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -41 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 42 points higher than the general drug manufacturer industry average of 44. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -42.14% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -33 percentage points.

Are general drug manufacturer stocks a good buy now?

38.46% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 50.22% over the next year.

5.56% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 50% of general drug manufacturer stocks are rated B (Buy), 38.89% are rated C (Hold), 0% are rated D (Sell), and 5.56% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 39.03x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.